Back to search
Osteoporosis, Postmenopausal
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Osteoporosis, Postmenopausal trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Osteoporosis, Postmenopausal trials you may qualify forIn this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmen…
The aim of the present clinical trial is to examine the effects of everolimus, resistance training, or their combination on bone and muscle health formation in…
During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to b…
Osteoporosis is a progressive disease characterised by a decrease in bone mass, deterioration in bone microarchitecture, and increased fragility. Etiologically,…
Dietary interventions of prune consumption during the transmenopausal period are innovative methods to prevent bone loss. Modern medicine does not intervene to…
Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected i…
Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
This study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women. Par…